Chugai Pharmaceutical (OTCMKTS:CHGCY) Shares Gap Down - Here's Why

Key Points

• Chugai Pharmaceutical's stock price gapped down from $22.62 to $21.31 before opening, with the last traded price at $21.99.
• The company reported $2.01 billion in revenue for the last quarter and an earnings per share (EPS) of $0.20.
• Chugai Pharmaceutical has a market capitalization of $72.14 billion and a PE ratio of 27.75.

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY - Get Free Report)'s stock price gapped down before the market opened on Thursday . The stock had previously closed at $22.62, but opened at $21.31. Chugai Pharmaceutical shares last traded at $21.99, with a volume of 111,804 shares trading hands.

Chugai Pharmaceutical Stock Performance

The company's fifty day simple moving average is $22.75 and its two-hundred day simple moving average is $24.40. The stock has a market capitalization of $72.14 billion, a PE ratio of 27.75 and a beta of 0.65.

Chugai Pharmaceutical (OTCMKTS:CHGCY - Get Free Report) last released its quarterly earnings results on Thursday, July 24th. The company reported $0.20 earnings per share (EPS) for the quarter. Chugai Pharmaceutical had a net margin of 33.08% and a return on equity of 20.80%. The company had revenue of $2.01 billion for the quarter. Sell-side analysts forecast that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 0.74 EPS for the current fiscal year.

About Chugai Pharmaceutical

Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.